Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
Subscribe To Our Newsletter & Stay Updated
